Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.33), $0.11 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $12.1 million versus the consensus estimate of $18.34 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.